Although antibody–drug conjugates (ADC) have transformed the standard of care for patients with metastatic urothelial carcinoma, primary and acquired resistance remain major obstacles to achieving ...

Copyright held by the owner/author(s).

Abstract:. For people with localized, high-risk prostate cancer, treatment with 6 months of apalutamide and androgen deprivation therapy (ADT) both before and after surgery reduces the risk of ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Antibody Drug Conjugates (ADC) are a clinically validated therapeutic modality for solid tumors relying on an antibody that targets a tumor-specific antigen to internalize and deliver cytotoxic agents ...

Abstract. Philadelphia-negative myeloproliferative neoplasms are chronic blood neoplasms. Treatments control blood counts but disease can progress to myelofibrosis or acute myeloid leukaemia. We ...

Cancer Res (2026) 86 (8_Supplement): LB407.

13Huntsman Cancer Institute, Salt Lake City, UT.

Abstract. High-throughput screening (HTS) of cereblon (CRBN) molecular glue (MG)-biased libraries remains a key strategy for proof-of-concept studies and hit identification against emerging targets.

Abstract. Current standards of care for metastatic clear cell renal cell carcinoma (ccRCC) include immune checkpoint inhibitors (ICIs), VEGFR-tyrosine kinase inhibitors (VEGFR-TKIs), or the ...

Cancer Res (2026) 86 (7_Supplement): 2894. Immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs) and neutrophils (TANs) contribute to resistance against immune checkpoint ...

Search for other works by this author on: ...